Organon & Co.
NYSE:OGNDrug Manufacturers - General
+$0.01 today
- Market cap
- $3.66B
- Beta
- 1.54
- P/E (TTM)
- 14.2
- EPS (TTM)
- $0.94
- Dividend yield
- 0.60%
Volume 3.90M
Average 8.57M
OGN Total Non-current Liabilities
All obligations due after more than one year.
Organon & Co.NYSE: OGN
Total Non-current Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total non-current liabilities falls 4.1% from a year ago
Total non-current liabilities stood at $9.56B at the end of Q3 FY2026, down 4.1% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +1.4% a year.
Context
- Total non-current liabilities amounted to 71.3% of total assets at the end of Q3 FY2026, down 2.2 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -4.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 9.73B USD
- Year-over-year change
- -1.9%
- 4-year CAGR
- +0.3%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.73B | -1.9% |
| FY2024 | 2024-12-31 | 9.91B | +7.6% |
| FY2023 | 2023-12-31 | 9.21B | -1.3% |
| FY2022 | 2022-12-31 | 9.34B | -2.7% |
| FY2021 | 2021-12-31 | 9.59B | — |
Total Non-current Liabilities vs competitors
How OGN compares with its peers on the latest reported figures
- OGN's Sep 2026 total non-current liabilities of $9.56B is the highest of the 10 companies compared; the peer median is $403.88M.
- Its year-over-year change of -4.1% is the 6th highest of 10, against a peer median of -2.4%.
- Total non-current liabilities amounts to 71.3% of total assets for OGN, versus a peer median of 35.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $9.56B | -4.1% | +1.4% | 71.3% | |
| Mar 2026 | $2.97B | +9.6% | -17.9% | 49.1% | |
| Mar 2026 | $1.44B | +12.6% | +6.2% | 101.6% | |
| Mar 2026 | $801.42M | +2.1% | +17.8% | 55.5% | |
| Sep 2026 | $754.07M | -17.7% | -3.6% | 35.2% | |
| Jun 2026 | $403.88M | +94.2% | +275.6% | 54.2% | |
| Feb 2026 | $291.57M | -54.0% | -19.7% | 14.1% | |
| Jun 2026 | $139.77M | -9.7% | -8.1% | 10.2% | |
| Jun 2026 | $77.51M | -12.9% | +58.2% | 9.8% | |
GRDNGuardian Pharmacy Services, Inc. | Jun 2026 | $31.89M | -2.4% | -20.7% | 7.2% |
| Peer median (excluding OGN) | $403.88M | -2.4% | -3.6% | 35.2% | |
Competitors are the stored peer set for OGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 737M | 706M | 693M | 675M | 574M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.51B | 1.61B | 1.86B | 1.49B | 1.43B |
| Inventory | 915M | 1B | 1.32B | 1.32B | 1.41B |
| Other Current Assets | 596M | 616M | 643M | 861M | 939M |
| Total Current Assets | 3.76B | 3.93B | 4.51B | 4.35B | 4.35B |
| Property, Plant & Equipment (Net) | 1.2B | 1.23B | 1.36B | 1.33B | 1.3B |
| Goodwill | 4.6B | 4.6B | 4.6B | 4.68B | 4.15B |
| Intangible Assets | 651M | 649M | 533M | 1.41B | 1.13B |
| Long-term Investments | 0 | 0 | 0 | 27M | 0 |
| Tax Assets | 0 | 267M | 808M | 946M | 0 |
| Other Non-current Assets | 464M | 272M | 250M | 361M | 1.93B |
| Total Non-current Assets | 6.92B | 7.02B | 7.55B | 8.75B | 8.52B |
| Total Assets | 10.68B | 10.96B | 12.06B | 13.1B | 12.87B |
| Account Payables | 1.38B | 1.13B | 1.31B | 1.15B | 952M |
| Short-term Debt | 55M | 57M | 55M | 64M | 56M |
| Tax Payables | 185M | 184M | 206M | 134M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 975M | 1.14B | 1.34B | 1.37B | 1.3B |
| Total Current Liabilities | 2.6B | 2.51B | 2.92B | 2.72B | 2.39B |
| Long-term Debt | 9.13B | 8.91B | 8.75B | 8.86B | 8.64B |
| Deferred Tax Liabilities | 4M | 19M | 47M | 74M | 57M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 279M | 261M | 287M | 865M | 924M |
| Total Non-current Liabilities | 9.59B | 9.34B | 9.21B | 9.91B | 9.73B |
| Total Liabilities | 12.19B | 11.85B | 12.13B | 12.63B | 12.12B |
| Common Stock | 3M | 3M | 3M | 3M | 3M |
| Retained Earnings | (998M) | (331M) | 443M | 1.01B | 1.11B |
| Accumulated OCI | (513M) | (564M) | (541M) | (649M) | (527M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (1.51B) | (892M) | (70M) | 472M | 752M |
| Total Debt | 9.36B | 9.11B | 8.93B | 9.04B | 8.8B |
| Net Debt | 8.63B | 8.41B | 8.24B | 8.36B | 8.23B |
Organon & Co.
NYSE:OGN
Intrinsic Alpha fair value
Locked
Current Price
$13.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.